Mike joined the board of Ossianix in 2013. He is a co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of Biopharmaceuticals Research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on molecular aspects of the immune system. He has more than 150 publications and membership of the European Molecular Biology Organisation and Fellowship of the Academy of Medical Sciences. Mike has been an independent director of Zealand Pharma A/S since 2012 and is also a member of the Board of BLINK Therapeutics (UK). Mike obtained a PhD from Cambridge University where he studied amino acid transport in trypanosomes, and a BA in Biochemistry from Keble College, Oxford University.
Frank is an accomplished Pharma and Biotech senior executive with over 20 years experience. Between 2002 and 2009, he was with Wyeth (Collegeville PA, USA), where he served as Executive Vice President and Head of Discovery Research Worldwide. This involved managing more than 1500 scientists across seven sites globally and delivering multiple products in diverse areas to IND and late stage clinical trials. Prior to joining Wyeth, Frank was at GlaxoSmithKline (UK) where he was Senior Vice President and Head of the Neurology Centre of Excellence for Drug Discovery. From 1997 to 2000, he was Vice President and Head of Neuroscience Research at SmithKline Beecham (UK). Before moving to industry, Frank had a distinguished academic career, during which he authored over 200 scientific publications. He was the Research Dean at the United Medical and Dental Schools of Guys and St. Thomas’ Hospitals (London, UK), and also the Sir William Dunn Professor of Experimental Pathology and previously worked at the Institute of Neurology Queen Square, London. He has honorary degrees from the University of Perugia, University of Bologna, University of Strathclyde and University of Dundee. He is a Fellow of King’s College London, a Fellow of the Academy of Medical Sciences London and a Corresponding Fellow of the Royal Society of Edinburgh.
Corey is a managing partner at venBio and has spent most of the last 15 years in Pharma and Biotech. He is currently Chairman of Oligasis, Solstice, Second Genome and Labrys Biologics. In 2007 he joined Pfizer as President and Founder of the Biotherapeutics and Bioinnovation Center, a new division focusing on Biologics and was a member of Pfizer’s Executive Leadership Team reporting to the CEO. He designed and built a new entrepreneurial R&D model with a focus on discovering and developing new therapeutics for unmet medical needs, and fostering innovation and game-changing technology. Corey founded two companies Exelixis and Renovis and led Renovis as President and CEO from a private to public company until its acquisition by Evotec. He obtained a BS from Stanford University and a PhD from UC Berkeley and spent 25 years as Professor of Neurobiology at Stanford. He became the Evan Rauch chair at UC Berkeley where he was a Howard Hughes Investigator and co-founder and director of the Wills Neuroscience Institute. He is the author of over 200 scientific papers. Corey is a member of the National Academy of Sciences and the American Philosophical Society. He has received many honours including the Alan T. Waterman award, the Canadian Gairdner Biomedical Award, the March of Dimes Prize and the Reeve-Irvine Research Medal.
Kim Andersen, PhD, is Vice President of Neuroscience Drug Discovery DK. He heads Lundbeck’s Danish drug discovery site and is member of Lundbeck’s R&D Executive Committee as well as the global Research and Development Committees. Kim started his career with Lundbeck in 1989 and has held different positions within Medicinal Chemistry including five years as head of department in Denmark and as Vice President of Medicinal Chemistry at Lundbeck Research USA, Inc. (formerly Synaptic Pharmaceuticals). In 2006 he returned to the headquarters in Denmark and took on the position as Director of Research Operations and Project Portfolio Management Research, a position he held until becoming Vice President of the Danish research site in 2008. Kim holds an MSc in Chemical Engineering and a PhD from the Danish School of Pharmacy, Copenhagen.